Navigation Links
GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
Date:10/20/2008

ATLANTA, Oct. 20 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced today it has shipped both DNA and MVA components of its AIDS vaccine to the HIV Vaccine Trials Network (HVTN) pharmacy, for use in the upcoming Phase 2a human clinical trial. This Phase 2a study will involve 150 vaccinees and 75 placebo (control) participants. These trials serve as a major milestone, as Phase 2a trials are the most advanced trials to-date for GeoVax.

Dr. Robert McNally, President and CEO of GeoVax Labs Inc., commented, "The shipment of the vaccine to the HIV Vaccine Trials Network is a significant step in preparation for the largest clinical trial yet to be undertaken by GeoVax. Multiple completed Phase 1 safety trials refined the dose and vaccine delivery intervals to optimize the immune responses considered desirable to achieve protection against the HIV-1 virus causing AIDS."

Further, a Biological Master File has been submitted to the Food and Drug Administration (FDA) for review of the manufacturing data for the product shipped to HVTN for use in the Phase 2a trial. The FDA completes its review within four weeks. Upon FDA clearance, HVTN's pharmacy will release GeoVax's DNA and MVA vaccines for its planned Phase 2a trial commencement.

GeoVax AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS) caused by the virus known as HIV-1 by vaccinating individuals prior to virus infection. The vaccine regimen employs a two component "prime-boost strategy." Trial participants are first administered GeoVax HIV-1 DNA vaccine which "primes" the immune system followed by the second vaccine, GeoVax's HIV-1 MVA (Modified Vaccinia Virus) boost. Both vaccines express the 3 major proteins of the AIDS virus. These proteins mimic more than 50% of the
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines
2. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
3. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
4. Nanoemulsion vaccines show increasing promise
5. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
6. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
7. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
8. Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016
9. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
10. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
11. GeoVax Presents Data at AIDS Vaccine 2008 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Dr. Sparano is Professor of Medicine and ... Albert Einstein College of Medicine and Associate Chairman of ... He is also Associate Director for Clinical Research ... Breast Cancer Working Group, a multidisciplinary group of physicians ... also serves as Vice Chair of the National Cancer ...
(Date:5/17/2013)... available in German . ... the naked eye, you can see which branch a bird ... of branches through the telephoto lens for high-magnification images requires ... are looking to study proteins, the active biomolecules of cells. ... for Molecular Systems Biology, and her colleagues have now come ...
(Date:5/17/2013)... USA (PRWEB) May 17, 2013 •    First ... Globes Certified for sustainability ,     New facility will ... , Syngenta unveiled its new ... at the company’s RTP Innovation Center. The first of ... researchers to simulate any agricultural climate and precisely measure ...
(Date:5/17/2013)... , May 17, 2013  Yongye International, Inc. ... a leading developer, manufacturer, and distributor of crop nutrient ... , today announced that, on May 16, 2013, ... of directors (the "Board of Directors") was provided a ... Hong Kong ) Limited ("Abax") to Full ...
Breaking Biology Technology:Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4
... patient monitors and sensors, reported a net loss of $245,000 ... $6 million. , ,Sales were down from nearly $6.6 million ... also down, and the firm's net loss came down from ... at about $3.7 million. , ,Criticare (AMEX:CMD) said that several ...
... Now that spring is in gear, women looking for new ... a "shorts and tee shirts" alternative to the traditional conference ... until Sunday, with yoga in the mornings and two full ... of summer camp. ... Your physical surroundings and the things ...
... the Alzheimer's disease drug market in the United ... percent annually for the next five years. , ... Markets for Alzheimer's Disease Medications 2005," include Pfizer, ... Alzheimer's drug market that generated more than $1.3 ...
Cached Biology Technology:Women in technology confab comes to Wisconsin 2Alzheimer's drug market to hit $5.5 billion by 2009, study says 2
(Date:5/17/2013)... finds human-caused climate change may have little impact ... host of recent studies that predict their widespread ... findings, which appear in the journal Global ... of a creature thought to be doomed: ... animals, especially forest lizards, will be hard hit ...
(Date:5/16/2013)... MD FASEB MARC (Maximizing Access to Research ... for The Society for Developmental Biology (SDB) 72nd ... 2013. These awards are meant to promote the ... groups into the mainstream of the basic science ... scientists at the SDB 2013 Annual Meeting. , ...
(Date:5/16/2013)... lining the body,s blood vessels, is extremely resilient. ... this super-tenuous structure routinely withstands blood flow, hydrostatic ... unique and highly dynamic barrier that maintains the ... circulatory system. , It,s also extremely adaptable. In ... to enable immune cells to reach various ...
Breaking Biology News(10 mins):Climate change may have little impact on tropical lizards 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... release is also available in German . ... of Germany,s plant species could lose parts of its ... Centre for Environmental Research (UFZ), the Potsdam Institute for ... Alpine reveals. Species distributions will be rearranged as a ...
... harnessed the sensitivity of days-old fish embryos to create ... chemicals. By measuring rates of oxygen use in ... conditions, the technology could reveal the presence of minute ... and substantial harm. It could be used as an ...
... sparking food and water shortages in the Middle East ... by an Australian climate scientist suggesting that rainfall will ... Recent projections from the Intergovernmental Panel on Climate Change ... Mediterranean would decline this century if global warming continues ...
Cached Biology News:Climate change threatens 1 in 5 plant species 2Using live fish, new tool a sentinel for environmental contamination 2Using live fish, new tool a sentinel for environmental contamination 3Climate change may boost Middle East rainfall 2
Blot Paper 7 x 8.5cm semi-dry western blots (order number RB-400)...
... capped transcripts with the translation boosting Cap ... 100% capped (versus 40% to 80% capped ... about 2 hours. mScript™ also features the ... to be up to 50% more efficient ...
Immunogen: Synthetic peptide: M(1) C V P R S G L I L S(11) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Immunogen: Recombinant full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: